

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT**  
**APPROVAL FOR CLINICAL TRIALS OF THE 20-VALENT**  
**PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company of the latest business developments of the Group.

Building upon its 13-valent pneumococcal conjugate vaccine, the Group has developed an optimized and upgraded iterative 20-valent pneumococcal conjugate vaccine, which has recently received the Notice of Approval for Drug Clinical Trials (《藥物臨床試驗批准通知書》) issued by the National Medical Products Administration, authorizing the commencement of clinical trials.

Pneumococcal disease is one of the most serious public health issues worldwide and a major cause of illness and death among children and adults in China. The primary clinical treatment for pneumococcal disease involves antibiotics. However, due to the widespread use of antibiotics, the drug resistance of pneumococcus has become increasingly severe. Therefore, the adoption of pneumococcal vaccines to prevent pneumococcal diseases and reduce bacterial resistance is particularly necessary and urgent. Pneumococcus is the primary pathogen responsible for severe illnesses in children, including pneumonia, meningitis and bacteremia, and is also a common cause of acute otitis media and sinusitis. According to WHO's estimates, approximately 8.8 million children under the age of five died worldwide in 2008, with about 476,000 of these deaths attributable to pneumococcal infection. The latest research published in 2018 indicated that approximately 294,000 children under five died from pneumococcal infection globally, with incidence and mortality rates higher in developing countries and regions than those in developed ones. The majority of these deaths occurred in Africa and Asia. Pneumococcal disease also remains a significant cause of illness and death among infants, young children and the elderly in China. The ten countries with the highest number of pneumococcal disease cases among children under the age of five are all located in Africa

and Asia, accounting for 66% of the total global cases, while China ranks second, accounting for 12% of the total global cases. In its classification of vaccine-preventable diseases, the WHO designates pneumococcal disease as a condition requiring “extremely high priority” for vaccine prevention.

Leveraging its polysaccharide conjugate vaccine technology platform, the Group has developed a series of iterative pneumonia vaccines through continuous technological upgrades and innovation. Building upon the 13-valent pneumococcal conjugate vaccine, it has developed an optimized and upgraded iterative 20-valent pneumococcal conjugate vaccine, which incorporates seven additional serotypes, covering a total of 20 currently predominant pneumococcal serotypes. It is indicated for the prevention of invasive diseases (such as pneumonia, meningitis and bacteremia) caused by these serotypes. Intended for individuals aged 2 months (minimum 6 weeks) and older, it prevents infectious diseases caused by the 20 pneumococcal serotypes covered by this product. Currently, only the Prevenar 20 by Pfizer is approved for marketing abroad worldwide and no comparable vaccine product has yet received approval for marketing in China.

The iterative 20-valent pneumococcal conjugate vaccine has been approved for clinical trials, marking a further expansion and enhancement of the Group’s R&D pipeline in the pneumococcal vaccine field. Moving forward, the Group will continue to focus on unmet clinical needs in core disease areas, advance the R&D of innovative vaccines, further strengthen the Company’s innovation capabilities, core competitiveness and overall strength, and deliver more safe and effective vaccine products, contributing to global disease prevention and control efforts.

By order of the Board  
**AIM Vaccine Co., Ltd.**  
*Chairman of the Board and CEO*  
**Mr. Yan ZHOU**

Beijing, the PRC, January 19, 2026

*As at the date of this announcement, the Board comprises Mr. Yan ZHOU, Mr. Xin ZHOU, Mr. Shaojun JIA, Mr. Wen GUAN and Mr. Jie ZHOU as executive directors; Mr. Jichen ZHAO as non-executive director; and Professor Ker Wei PEI, Ms. Jie WEN and Mr. Xiaoguang GUO as independent non-executive directors.*